Search peptides, terms, sources/
Research source · 2015

Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial

About this source

Kind
Research
Design
RCT, Human clinical trial
Population
Human, severe dry eye including graft-versus-host disease, 9 patients (RGN-259 group 12 eyes, vehicle group 6 eyes), 2 US sites
Sample size
9
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

Nine patients. The abstract gives no adverse-event counts and states only that the drops were safe and well tolerated. Verified from the Europe PMC abstract record.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.